G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
Details on the poster are as follows:
Title: Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results
Abstract Number: 8568
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Number: 304
Date / Time:
Saturday, June 3, 8 a.m.– 11:30 a.m. CDT
McCormick Place, Hall A
Caio Max S. Rocha Lima, M.D.; Spartanburg Regional Healthcare System
Additional information on the meeting can be found on the
About Trilaciclib (G1T28)
Trilaciclib is a potential first-in-class short-acting CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. Trilaciclib is administered intravenously prior to chemotherapy and has the potential to significantly improve treatment outcomes.
Trilaciclib is being evaluated in four randomized Phase 2 clinical trials: a study in newly diagnosed, treatment-naive small-cell lung cancer (SCLC) patients (NCT02499770), a study in previously treated SCLC patients (NCT02514447), a study in combination with atezolizumab and chemotherapy in SCLC patients (NCT03041311) and a study in patients with triple-negative breast cancer (NCT02978716).
G1 is based in
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to trilaciclib’s potential ability to significantly improve treatment outcomes, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Robert Uhl Westwicke Partners858-356-5932 email@example.com Media: Laura Bagby6 Degrees Communications312-448-8098 firstname.lastname@example.org